Aripiprazole

Recent articles

Book cover conceptual illustration of chromosome superimposed with genetic tree.

A whisper of autism: Fragile X carriers and the autism phenotype

Among people who carry the fragile X premutation, about 14 percent of boys and 5 percent of girls meet the criteria for autism, but the ‘broad autism phenotype’ may be far more common.

By Anne Skomorowsky
21 April 2022 | 14 min read
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: An ineffective therapy and an effective biomarker

In this edition, a strategy to help autistic children adapt their skills to new situations shows no benefit, but an early-life autism biomarker does.

By Laura Dattaro
6 April 2022 | 4 min read

Q&A with W. David Lohr: Antipsychotics, polypharmacy among autistic preschoolers

Hundreds of preschool-aged children in Kentucky began taking antipsychotic medicines in 2012, according to an analysis of Medicaid records. Lohr discusses what it will it take to get them behavioral therapies instead.

By Niko McCarty
21 September 2021 | 3 min read
Pregnant woman holding two white pills in her hand.

Prenatal exposure to antipsychotic medication does not increase odds of autism, ADHD

Children born to mothers who take antipsychotic drugs during pregnancy are not more likely to have autism or attention deficit hyperactivity disorder, or to be born preterm or underweight.

By Peter Hess
20 August 2021 | 2 min read
Brain and marijuana leaves

Q&A with Eric Hollander: Cannabis treatments for autism

As cannabis prohibition slowly lifts in the United States, scientists and families in the autism community are increasingly turning to the drug and its constituent compounds to ease autism-related difficulties, including seizures and irritability.

By Peter Hess
8 June 2021 | 6 min read
Pills spilling out of falling prescription bottle.

Spectrum reporting prompts new review of common drug

Aripiprazole, an antipsychotic medication marketed as Abilify, eases aggressive behavior in autistic children, but questions remain about its side effects.

By Jaclyn Jeffrey-Wilensky
29 January 2021 | 11 min read
researcher facing off with the coronavirus.

Rewind: Spectrum’s best from 2020

Our staff picks the stories, podcasts and special reports that stood out from the rest this past year.

By Spectrum
23 December 2020 | 5 min read
Colorful figure with a circle shape (a pill) and an orange X in the background symbolizing Fragile X

Diabetes drug delivers multiple benefits for people with fragile X syndrome

Researcher Randi Hagerman is a big proponent of metformin — a diabetes drug that she is testing in people with fragile X syndrome. In fact, Hagerman takes the drug herself as a preventive measure against cancer.

By Polina Porotskaya
17 September 2019 | 6 min read

Clinicians should consider off-label treatments for autism

Clinicians need a more consistent and evidence-based approach to prescribing antipsychotics to children and adolescents with autism.

By Maurizio Bonati
7 May 2019 | 5 min read

Explore more from The Transmitter

Abstract illustration of a human brain.

‘Elusive Cures: Why Neuroscience Hasn’t Solved Brain Disorders—and How We Can Change That,’ an excerpt

In her new book, published today, neuroscientist Nicole Rust takes us on her personal quest to spell out the brain research community's "Grand Plan."

By Nicole Rust
10 June 2025 | 9 min read
Illustration of an open journal featuring lines of text and small illustrations of eyes and mouths.

Convergent effects of autism-linked genes in zebrafish; and more

Here is a roundup of autism-related news and research spotted around the web for the week of 9 June.

By Jill Adams
10 June 2025 | 2 min read
Research image containing repeated structures, suggesting potential image manipulation.

More than two dozen papers by neural tube researcher come under scrutiny

One of the studies, published in 2021 in Science Advances, received an editorial expression of concern on 21 May, after the journal learned that an institutional review of alleged image problems is underway.

By Claudia López Lloreda
9 June 2025 | 6 min read